科兴制药(688136.SH)：人干扰素α 1b吸入溶液纳入突破性治疗品种名单

Core Viewpoint - The announcement highlights that the inhalation solution of human interferon α 1b, developed by the company's wholly-owned subsidiary, has been included in the list of breakthrough therapies by the National Medical Products Administration [1] Group 1: Product Development - The human interferon α 1b inhalation solution is a significant breakthrough in the antiviral field for the company [1] - This medication is specifically designed for children and is administered via nebulization, allowing the active ingredient to reach the site of infection more quickly [1] - Compared to injectable forms, this inhalation solution offers higher acceptance and safety for pediatric patients, as they do not have to endure the pain of injections [1] Group 2: Indications and Applications - The indication for the human interferon α 1b inhalation solution is for pediatric respiratory syncytial virus (RSV) lower respiratory tract infections, including pneumonia and bronchiolitis [1]